Condition: Vulvar Cancer · Sponsor: Akeso
This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.
This description comes directly from the study's public registry record.
Ting Liu, MD · +86(0760)89873999 · clinicaltrials@akesobio.com
Always discuss trial participation with your own doctor first.
| Clinical oncology school of Fujian Medical University, Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Sun Yant-Sen Memorial Hospital | Guangzhou, Guangdong, China | Recruiting |
| The Fourth Hospital of Hebei Medical University | Shijiangzhuang, Hebei, China | Not Yet Recruiting |
| Liaoning Cancer Hospital & Insitut | Shenyang, Liaoning, China | Recruiting |
| Tianjin medical university Cancer Institut & Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05932212